Dr. Manal El-Sayed (Cairo, Egypt) is Professor of Pediatrics at Ain Shams University. She is the director of the clinical research center (MASRI-CRC) and co- supervisor of the viral hepatitis treatment center at the faculty of Medicine, Ain Shams University and clinical director of the national HCV Pediatric treatment program. Manal has worked with pediatric hematology and oncology teams at Ain Shams University, National Cancer Institute, and 57357 Children’s Cancer Hospital since 1990.

Dr El-Sayed is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. She contributed to the establishment of a nationwide network of more than 55 specialized liver centers that provided interferon therapy to 350,000 HCV-infected patients. Since 2014 when the NCCVH introduced the new direct-acting antiviral agents for HCV, more than 3 million patients have been treated. Manal collaborated on the development of the national action plan for prevention and control of viral hepatitis published in October 2014 with representatives from WHO, the U.S. Centers for Disease Control and Prevention (U.S. CDC), Pasteur Institute, and national stakeholders. In addition to co-supervising the nationwide mass screening program for adults and children reaching so far more than 56 million people recently published in the New England Journal.

Manal is also an active board member and secretary general of the Egyptian Liver Care Society, a non-governmental organization that offers financial assistance to patients receiving treatment for hepatitis or liver transplants. She has authored and co-authored numerous journal articles on hepatitis and liver diseases, and participated in the development of all global WHO’s HBV, HCV and diagnostic guidelines. She is an editorial board member of Hepatology Journal affiliated to the American Study of Liver Disease Association and a reviewer for numerous high impact journals. Between 2011- 2015, Manal was Vice Chair of WHO’s Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt and has been acting as a WHO consultant for viral hepatitis strategy planning for several countries and has been a member of the Global Accelerator for Pediatric Formulations (GAP-f) since December 2016. She is also a board member of the European Study of Liver Disease International Liver Foundation since January 2018 planning and implementing viral hepatitis micro-elimination models in different countries. In addition to co-organizing and co-chairing numerous international meetings on viral hepatitis and liver disease in Europe and Africa. El- Sayed is also an oversight committee member of the EndHep2030 initiative since the beginning of 2019.